TABLE 9.
Major Studies Specifically Reporting EGFR Mutation Analysis in Surgically Resected Squamous Cell Carcinomas as Compared to Adenocarcinomas
| Source, y | Predominant Ethnic Origin of Study Population | EGFR Mutations in Resected Adenocarcinomas, No. (%) | EGFR Mutations in Resected Squamous Cell Carcinomas, No. (%) |
|---|---|---|---|
| Marchetti et al,45 2005 | European | 39/375 (10.4) | 0/454 |
| Sugio et al,43 2006 | Asian | 136/322 (42.2) | 0/102 |
| Tsao et al,44 2006 | North American | 14/96 (14.6) | 0/63 |
| Tsao et al,60 2011 | North American | 32/231 (13.9) | 8/162 (4.9) |
| Bae et al,284 2007 | Asian | 20/55 (36.4) | 0/60 |
| Lee et al,300 2010 | Asian | 36/117 (30.8) | 0/56 |
| Miyamae et al,301 2011 | Asian | … | 3/87a (3.4) |
| Rekhtman et al,36 2012 | North American | … | 0/95 |
| TCGA,302,b 2012 | North American | … | 2/178c (1.1) |
a
These numbers do not include 2 EGFR-mutated cases reclassified as adenocarcinoma and adenosquamous carcinoma on the basis of immunohistochemistry (IHC) for thyroid transcription factor 1 (TTF-1)/p63; the remaining 3 EGFR-mutated cases were reported as IHC-confirmed squamous cell carcinoma.
b
The Cancer Genome Atlas Research Network.
c
Both EGFR mutations were L861R.